Vertex Is Buying Crinetics for $10 Billion. Here's What Investors Need to Know.
The drugmaker is paying up for a new growth engine. Is the price disciplined?
Overview
Vertex Pharmaceuticals (NASDAQ: VRTX) is making its biggest bet in years. On Monday, the company agreed to acquire Crinetics Pharmaceuticals (NASDAQ: CRNX) for $85 per share in cash. That works out to a total equity value of about $10 billion, or roughly $8.8 billion net of the cash Crinetics holds. Both companies' boards approved the deal unanimously, and Vertex expects it to close in the third quarter of 2026.
For a company that has spent decades built almost entirely around cystic fibrosis, this is a meaningful step into a new disease area. Here's what the deal buys, how Vertex is paying for it, and whether the price looks reasonable.
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.